{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:37:26Z","timestamp":1773387446408,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtos.2023.07.005","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T15:59:33Z","timestamp":1689609573000},"page":"550-556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identifying patient-valued outcomes for use in early phase trials of ocular surface disease interventions"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-7741","authenticated-orcid":false,"given":"Anita L.","family":"Slade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9708-2588","authenticated-orcid":false,"given":"Alberto","family":"Recchioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-8251","authenticated-orcid":false,"given":"Olalekan L.","family":"Aiyegbusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-8386","authenticated-orcid":false,"given":"Ameeta","family":"Retzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-8799","authenticated-orcid":false,"given":"Laura","family":"Nice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Dancey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-837X","authenticated-orcid":false,"given":"Melanie J.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-3496","authenticated-orcid":false,"given":"Saaeha","family":"Rauz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtos.2023.07.005_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"Miljanovi\u0107","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2023.07.005_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ajo.2013.05.040","article-title":"Prevalence of dry eye disease and its risk factors in visual display terminal users: the osaka study","volume":"156","author":"Uchino","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2023.07.005_bib3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/opo.12888","article-title":"The global prevalence of dry eye disease: a Bayesian view","volume":"41","author":"Papas","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"issue":"3","key":"10.1016\/j.jtos.2023.07.005_bib4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.jtos.2023.07.005_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in europe, North America, and Asia: a systematic literature review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocul Surf"},{"issue":"4","key":"10.1016\/j.jtos.2023.07.005_bib6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtos.2016.06.001","article-title":"Patients' perspectives on their dry eye disease","volume":"14","author":"Crnej","year":"2016","journal-title":"Ocul Surf"},{"issue":"4","key":"10.1016\/j.jtos.2023.07.005_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10384-010-0812-2","article-title":"Dry Eye Survey Group of the National Hospital Organization of J. Association between clinical diagnostic tests and health-related quality of life surveys in patients with dry eye syndrome","volume":"54","author":"Mizuno","year":"2010","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2023.07.005_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) Instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1\u2014eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jtos.2023.07.005_bib9","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","article-title":"Patient-reported outcomes to support medical product labeling claims: FDA perspective","volume":"10","author":"Patrick","year":"2007","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jtos.2023.07.005_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) Instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1","volume":"14","author":"Patrick","year":"2014","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jtos.2023.07.005_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253857","article-title":"A systematic review assessing the quality of patient reported outcomes measures in dry eye diseases","volume":"16","author":"Recchioni","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jtos.2023.07.005_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1477-7525-9-111","article-title":"Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients","volume":"9","author":"Abetz","year":"2011","journal-title":"Health Qual Life Outcome"},{"issue":"5","key":"10.1016\/j.jtos.2023.07.005_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"21","key":"10.1016\/j.jtos.2023.07.005_bib14","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtos.2023.07.005_bib15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000514874","article-title":"The use of patient-reported outcome measures in phase I Oncology clinical trials","volume":"99","author":"Coleman","year":"2021","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.jtos.2023.07.005_bib16","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtos.2023.07.005_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41591-021-01648-4","article-title":"The value of patient-reported outcomes in early-phase clinical trials","volume":"28","author":"Retzer","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtos.2023.07.005_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41687-019-0172-8","article-title":"An emerging framework for fully incorporating public involvement (PI) into patient-reported outcome measures (PROMs)","volume":"4","author":"Carlton","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jtos.2023.07.005_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0149-7189(89)90016-5","article-title":"An introduction to concept mapping for planning and evaluation","volume":"12","author":"Trochim","year":"1989","journal-title":"Eval Progr Plann"},{"key":"10.1016\/j.jtos.2023.07.005_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.evalprogplan.2016.08.016","article-title":"The use of concept mapping in measurement development and evaluation: application and future directions","volume":"60","author":"Rosas","year":"2017","journal-title":"Eval Progr Plann"},{"key":"10.1016\/j.jtos.2023.07.005_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.evalprogplan.2016.10.006","article-title":"Introduction to a special issue on concept mapping","volume":"60","author":"Trochim","year":"2017","journal-title":"Eval Progr Plann"},{"key":"10.1016\/j.jtos.2023.07.005_bib24","series-title":"Concept mapping for planning and evaluation","author":"Kane","year":"2007"},{"issue":"2","key":"10.1016\/j.jtos.2023.07.005_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.evalprogplan.2011.10.003","article-title":"Quality and rigor of the concept mapping methodology: a pooled study analysis","volume":"35","author":"Rosas","year":"2012","journal-title":"Eval Progr Plann"},{"key":"10.1016\/j.jtos.2023.07.005_bib26","unstructured":"FDA. Patient-focused Drug development: collecting comprehensive and representative input. In: U.S. Department of health and human services FaDA, ed. Rockville MD2018."},{"key":"10.1016\/j.jtos.2023.07.005_bib27","series-title":"Silver spring, MD: center for biologics evaluation and research (CBER), office of communication","article-title":"Use of real-world evidence to support regulatory decision-making for medical devices, guidance for industry and Food and Drug administration staff","year":"2017"},{"key":"10.1016\/j.jtos.2023.07.005_bib28","doi-asserted-by":"crossref","unstructured":"Harman K.E., Barha J., Chalmers J.R., et al. The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership. Br J Dermatol 2023 May 18:ljad140. doi: 10.1093\/bjd\/ljad140. Epub ahead of print. PMID: 37201904.","DOI":"10.1093\/bjd\/ljad140"},{"issue":"12","key":"10.1016\/j.jtos.2023.07.005_bib29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jtos.2023.07.005_bib30","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012423000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012423000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T23:26:16Z","timestamp":1716420376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012423000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":28,"alternative-id":["S1542012423000915"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2023.07.005","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying patient-valued outcomes for use in early phase trials of ocular surface disease interventions","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2023.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}